FT improving ICI efficacy stems from the theory that FT expands the pool of tumor-specific CD8 effector T cells and reduce tumor immunosuppression, so there is more tumor-specific effector T cells to respond to ICI monotherapy. This evidence concerns the gene CD8A and neoplasm.